Besides those in vitro studies, presence of spontaneous CTL response against MHC class I restricted SV peptide antigens in patients with lung cancer (Giaccone et al., 2009), breast cancer (Yamanaka et al., 2011), glioma (Liu et al., 2018), and leukemia (Siegel et al., 2004) strongly indicate that CD8+ T cell restricted epitopes from SV are of substantial immunotherapeutic value. This evidence concerns the gene CD8A and glioma.